1Department of Surgery, Hanyang University College of Medicine, Seoul, Korea
2Division of Breast and Endocrine Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
3Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
4Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
5Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Copyright © 2018 by the Korean Cancer Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Characteristic | Negative margin (group 1) (n=3,195) | Positive superficial and/or deep margin (group 2) (n=121) | Positive peripheral parenchymal margin (group 3) (n=87) | p-value |
---|---|---|---|---|
Age at diagnosis (yr) | 47 (19-78) | 45 (29-71) | 45 (30-73) | 0.47 |
Follow-up period (mo) | ||||
Median | 88 | 81 | 88 | 0.86 |
Mean±SD | 92.6±26.6 | 91.0±25.7 | 91.7±23.7 | |
Tumor size (cm) | ||||
≤ 2 | 2,356 (73.7) | 89 (73.6) | 70 (80.5) | 0.37 |
> 2 | 839 (26.3) | 32 (26.4) | 17 (19.5) | |
Node metastasis | ||||
Negative | 2,419 (75.7) | 88 (72.7) | 71 (81.6) | 0.68 |
Positive | 776 (24.3) | 33 (27.3) | 16 (18.4) | |
Histologic grade | ||||
1/2 | 1,959 (66.1) | 84 (74.3) | 63 (77.8) | 0.02 |
3 | 1,003 (33.9) | 29 (25.7) | 18 (22.2) | |
Unknown | 5 | 0 | 0 | |
EIC present | ||||
No | 2,481 (81.3) | 86 (71.7) | 46 (55.4) | < 0.001 |
Yes | 571 (18.7) | 34 (28.3) | 37 (44.6) | |
Unknown | 143 | 1 | 4 | |
Hormone receptor status | ||||
Negative | 993 (31.3) | 21 (17.4) | 16 (18.4) | < 0.001 |
Positive | 2,180 (68.7) | 100 (82.6) | 71 (81.6) | |
Unknown | 21 | 0 | 0 | |
HER2 status | ||||
Negative | 2,244 (80.4) | 86 (78.9) | 59 (80.8) | 0.89 |
Positive | 546 (19.6) | 23 (21.1) | 14 (19.2) | |
Unknown | 371 | 12 | 14 | |
Hormone therapy | ||||
No | 880 (27.8) | 20 (16.5) | 15 (18.6) | 0.005 |
Yes | 2,285 (72.2) | 101 (83.5) | 67 (81.4) | |
Unknown | 30 | 0 | 1 | |
Chemotherapy | ||||
No | 1,277 (40.0) | 61 (50.4) | 46 (52.9) | 0.005 |
Yes | 1,918 (60.0) | 60 (49.6) | 41 (47.1) | |
Unknown | 1 | 0 | 0 |
Variable | HR (95% CI) | p-value |
---|---|---|
Age at diagnosis (yr) | < 0.001 | |
≥ 40 | 1 | |
< 40 | 2.59 (1.64-4.10) | |
Tumor size (cm) | 0.022 | |
≤ 2 | 1 | |
> 2 | 1.78 (1.09-2.92) | |
Node metastasis | 0.613 | |
No | 1 | |
Yes | 0.86 (0.48-1.54) | |
Histologic grade | 0.880 | |
1/2 | 1 | |
3 | 0.96 (0.57-1.63) | |
EIC present | 0.410 | |
No | 1 | |
Yes | 1.26 (0.73-2.17) | |
Hormone receptor status | < 0.001 | |
Positive | 1 | |
Negative | 2.90 (1.65-5.12) | |
Adjuvant chemotherapy | 0.139 | |
No | 1 | |
Yes | 0.62 (0.33-1.17) | |
Resection margin involvement | < 0.001 | |
Group 1 | 1 | |
Group 2 | 0.66 (0.16-2.72) | 0.566 |
Group 3 | 4.78 (2.27-10.09) | < 0.001 |
Group | Resection margin status |
LR site |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Free | In situ | Invasive | Both in situ and invasive | NA | Total No. of LRs | In breast |
Skin | Chest wall | ||
Same quadrant | Other quadrant | |||||||||
Group 1: no involvement on all resection margins (n=3,195) | 3,195 | - | - | - | - | 89 | 67 | 20 | 1 | 1 |
Group 2: involvement on superficial and/or deep resection margins (n=121) | - | 31 | - | - | - | 1 | 1 | - | - | - |
- | - | 76 | - | - | 1 | - | 1 | - | - | |
- | - | - | 1 | - | 0 | - | - | - | - | |
- | - | - | - | 13 | 0 | - | - | - | - | |
Group 3: involvement on conventional peripheral parenchymal resection margins (n=87) | - | 73 | - | - | - | 7 | 4 | 3 | - | - |
- | - | 9 | - | - | 0 | - | - | - | - | |
- | - | - | 4 | - | 1 | 1 | - | - | - | |
- | - | - | - | 1 | 0 | - | - | - | - |
Values are presented as median (range) or number (%) unless otherwise indicated. SD, standard deviation; EIC, extensive intraductal component; HER2, human epidermal growth factor receptor 2.
HR, hazard ratio; CI, confidence interval; EIC, extensive intraductal component.
LR, local recurrence; NA, not available.